Evidence map›Paper›PMID 35723286›Full record

ArticleThe journal of applied laboratory medicine2022

Automated Library Construction and Analysis for High-Throughput Nanopore Sequencing of SARS-CoV-2.

Robin J N Coope, Nancy Matic, Pawan K Pandoh, Richard D Corbett, Duane E Smailus, Stephen Pleasance, Christopher F Lowe, Gordon Ritchie, Samuel D Chorlton, Matthew Young and 9 more

Abstract read
In one paragraph

Article in The journal of applied laboratory medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Robin J N CoopeCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, BC, Canada.ORCID 0000-0002-4685-3506
Nancy MaticDepartment of Pathology and Laboratory Medicine, Saint Paul's Hospital, Vancouver, BC, Canada.
Pawan K PandohCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, BC, Canada.
Richard D CorbettCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, BC, Canada.
Duane E SmailusCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, BC, Canada.
Stephen PleasanceCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, BC, Canada.
Christopher F LoweDepartment of Pathology and Laboratory Medicine, Saint Paul's Hospital, Vancouver, BC, Canada.
Gordon RitchieDepartment of Pathology and Laboratory Medicine, Saint Paul's Hospital, Vancouver, BC, Canada.
Samuel D ChorltonDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Matthew YoungDepartment of Pathology and Laboratory Medicine, Saint Paul's Hospital, Vancouver, BC, Canada.
Adrian A AllyCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, BC, Canada.
Jennifer K AsanoCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, BC, Canada.
Rebecca E CarlsenCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, BC, Canada.
Sundeep S ChahalCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, BC, Canada.
Yongjun ZhaoCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, BC, Canada.
Daniel T HolmesDepartment of Pathology and Laboratory Medicine, Saint Paul's Hospital, Vancouver, BC, Canada.
Marc G RomneyDepartment of Pathology and Laboratory Medicine, Saint Paul's Hospital, Vancouver, BC, Canada.
Steven J M JonesCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, BC, Canada.
Marco A MarraCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, BC, Canada.ORCID 0000-0001-7146-7175

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo support the implementation of high-throughput pipelines suitable for SARS-CoV-2 sequencing and analysis in a clinical laboratory, we developed an automated sample preparation and analysis workflow.

methodsWe used the established ARTIC protocol with approximately 400 bp amplicons sequenced on Oxford Nanopore's MinION. Sequences were analyzed using Nextclade, assigning both a clade and quality score to each sample.

resultsA total of 2179 samples on twenty-five 96-well plates were sequenced. Plates of purified RNA were processed within 12 h, sequencing required up to 24 h, and analysis of each pooled plate required 1 h. The use of samples with known threshold cycle (Ct) values enabled normalization, acted as a quality control check, and revealed a strong correlation between sample Ct values and successful analysis, with 85% of samples with Ct < 30 achieving a "good" Nextclade score. Less abundant samples responded to enrichment with the fraction of Ct > 30 samples achieving a "good" classification rising by 60% after addition of a post-ARTIC PCR normalization. Serial dilutions of 3 variant of concern samples, diluted from approximately Ct = 16 to approximately Ct = 50, demonstrated successful sequencing to Ct = 37. The sample set contained a median of 24 mutations per sample and a total of 1281 unique mutations with reduced sequence read coverage noted in some regions of some samples. A total of 10 separate strains were observed in the sample set, including 3 variants of concern prevalent in British Columbia in the spring of 2021.

conclusionsWe demonstrated a robust automated sequencing pipeline that takes advantage of input Ct values to improve reliability.

Indexed as

COVID-19NanoporesNanopore SequencingHumansReproducibility of ResultsSARS-CoV-2

Identifiers

PMID35723286
PMCPMC9384306

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.